A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

The Environmental Protection Agency and the Department of Health and Human Services have announced they are launching a ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

Fara Dabhoiwala’s account of free speech from 1700 to the modern day is an ambitious feat, though his critique of America doesn’t stack up ...

The Centers for Medicare & Medicaid Services will not cover drugs when exclusively used for weight loss, like Ozempic or ...

Health and Human Services Secretary Robert F. Kennedy Jr. has been critical of the drugs, instead placing a focus on ...

Contrave and Wegovy are both weight loss medications. Learn about their effectiveness, side effects, costs, and which ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Ozempic and Wegovy are both GLP-1 injections that contain ... Note: After the FDA approves a medication, it tracks and reviews side effects of the drug. If you develop a side effect while taking ...